RxTeach
  • Home
  • Clinical Pharmacy
  • Journal Clubs
  • Pharmacy Industry
  • Health & Wellness
  • Students
  • Donations
  • About
  • Day in the Life
  • Science
  • Connect with us!
Sign in Subscribe
Clinical Pharmacy

ARTESIA Trial

The New England Journal of Medicine published the ARTESIA trial in January 2024. This post is going to be a journal club breaking down the ARTESIA trial and what change it may bring to our clinical practice.

  • Kristen Lindauer, PharmD, BCPS, AAHIVP

Kristen Lindauer, PharmD, BCPS, AAHIVP

21 Feb 2024 • 7 min read
ARTESIA Trial
Photo by Lucas K / Unsplash

This post is for subscribers only

Subscribe now

Already have an account? Sign in

The Andexxa Paradox

The Andexxa Paradox

Andexxa withdrawn after ANNEXA-I showed higher stroke risk; clinicians return to 4F-PCC for DOAC reversal while new agents emerge.
14 Jan 2026 5 min read
December Recap 2025
Paid-members only

December Recap 2025

We are back with another monthly post for our paid subscribers. In this post, we also share a number of fun things that are more personal, interesting, and meant to create a closer community around RxTeach.
09 Jan 2026 5 min read
Kaplan-Meier Curves in Oncology

Kaplan-Meier Curves in Oncology

Introduction Kaplan-Meier (KM) survival curves are foundational to oncology clinical trials and can be central to how efficacy is assessed for cytotoxic chemotherapy, targeted therapies, immunotherapies, and cellular therapies. Endpoints such as overall survival (OS), progression-free survival (PFS), event-free survival (EFS), and duration of response (DoR) are almost universally presented
07 Jan 2026 5 min read
RxTeach © 2026
Powered by Ghost